Q1 2025 Management View CEO Leonard Schleifer highlighted mixed performance in Q1 2025, with challenges in the retinal ...

Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug ...

The FDA has sent Regeneron a complete response letter, rejecting its bid to stretch the administration of high-dose Eylea ...

Regeneron founder, chair and CEO Leonard Schleifer joins 'Squawk Box' to discuss the impact of President Trump's tariff policies on biotech and pharmaceuticals, his thoughts on HHS Secretary RFK ...

Regeneron Pharmaceuticals, Inc. (REGN) announced on Tuesday that it has entered into a manufacturing and supply agreement ...

Swiss drugmaker Roche will spend $50B to expand its U.S. manufacturing, while New York-based Regeneron will spend more than ...

“I think you might hear some noise at the high policy level, but I’m hopeful that at the actual day-to-day decision-making ...

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics ...

Regeneron Pharmaceuticals has entered a new manufacturing and supply agreement with Fujifilm Diosynth Biotechnologies to ...

Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to ...

CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and ...